A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety,
tolerability, and pharmacokinetics (PK) of oral (PO) GDC-0941 administered in combination
with PO erlotinib in patients with advanced solid tumors and patients with locally advanced
or metastatic non-small cell lung cancer (NSCLC) who have failed at least one prior
chemotherapy regimen.